Anixa Biosciences Inc (ANIX) 10-Q Quarterly Report Wed Jun 12 2019

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Apr. 30, 2019	Jun. 11, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Anixa Biosciences Inc
Document Type	10-Q
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		20,096,743
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Apr. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/715446/000151316219000156/form10q.htm

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Financial

Revenue

Legal

Other

Filter by Subcategory:

All

Earnings

Product

Expense

Cash Flow

Income

Other

Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Other - Other Highlight
23 The net loss attributable to noncontrolling interest, representing Wistars 5% ownership interest in Certaintys net loss, increased by approximately $81,000 to approximately $122,000 in the six months ended April 30, 2019, from approximately $41,000 in the six months ended April 30, 2018, as Certaintys net loss increased.

Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistars 5% ownership interest in Certaintys net loss, increased by approximately $23,000 to approximately $37,000 in the three months ended April 30, 2019, from approximately $14,000 in the three months ended April 30, 2018, as Certaintys net loss increased.
Financial - Earnings Highlight
Accordingly, the earnings process from these licenses was complete and 100% of the revenue was recognized upon execution of the license agreement.
Financial - Earnings Highlight
Accordingly, the earnings process from these licenses was complete and 100% of the revenue was recognized upon execution of the license agreement.
Financial - Earnings Highlight
As such, the earnings process is complete and revenue is recognized upon the execution of the agreement, when collectability is probable and all other revenue recognition criteria have been met.
Revenue - Product
Cash provided by financing activities...Read more
Financial - Expense
The increase in research and...Read more
Financial - Expense
The increase in Certainty?s net...Read more
Financial - Expense
The increase in Certainty?s net...Read more
Financial - Cash Flow
We can give no assurance...Read more
Other - Other
As a result, our cash,...Read more
Financial - Cash Flow
The impairment in carrying amount...Read more
Financial - Expense
General and Administrative Expenses General...Read more
Financial - Expense
General and Administrative Expenses General...Read more
Financial - Expense
The increase in research and...Read more
Financial - Income
Interest income increased by approximately...Read more
Financial - Income
Interest income increased by approximately...Read more
Revenue - Product
Additionally, the sale of equity...Read more
Revenue - Product
We believe that, of the...Read more
Legal - Other
Inventor royalties, contingent legal fees,...Read more
Legal - Other
Inventor royalties, contingent legal fees,...Read more
Financial - Shares
If current cash on hand,...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001513162-19-000156
Submitted to the SEC: Tue Jun 11 2019 1:51:38 PM EST
Accepted by the SEC: Wed Jun 12 2019
Period: Tuesday, April 30, 2019
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-19-000156.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, April 30, 2019

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News